In non-small-cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangement treated with crizotinib, progression-free survival (PFS) varies according to the ALK fusion variant.
Disparities in the prevalence of EGFR mutations and ALK rearrangements by racial-ethnic group in South Florida with a focus on Hispanic patients, 2011-2019. This is an ASCO Meeting Abstract from the ...
Lung cancer, the leading cause of cancer-related mortality worldwide, poses significant challenges to patients, caregivers and health care professionals alike. This special issue of CURE provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results